Designed to the standards of a human heart.

Designed to the standards of a pig heart.

Carpentier-Edwards
PERIMOUNT
Pericardial Aortic Bioprosthesis

Why Compromise?
In patients over the age of 60, the actual risk of explant due to SVD is less than 10% at 20 years.1

![Freedom From Explant Due to SVD](chart)

Durability
- Exceptional durability to 20 years
- Consistent performance in a multitude of published studies

Tissue treatment
- Treated with XenoLogiX process, which removes binding sites for calcium
- Superior anticalcification results in animal studies†2,3 compared to any other commercially available valve treatment

Hemodynamic performance
- Largest EOA of any stented tissue valve†
- Unprecedented 17-year hemodynamic stability

† No clinical data are available which evaluate the long-term impact of the XenoLogiX treatment in patients.

1 No clinical data are available which evaluate the long-term impact of the XenoLogiX treatment in patients.

The PERIMOUNT bioprosthesis is the world’s most widely implanted tissue valve — period.
Why Compromise?

The PERIMOUNT bioprosthesis offers everything that matters most

In patients over the age of 60, the actual risk of explant due to SVD is less than 10% at 20 years.1

Duration Free of Valve Replacement

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Years Postoperative

92.6%

Uncompromised

Uncompromised

Uncompromised

Uncompromised

Uncompromised

Uncompromised

90%

80%

70%

60%

50%

40%

30%

20%

10%

0%

Freedom From Explant Due to SVD

The PERIMOUNT bioprosthesis is the world's most widely implanted tissue valve — period.

Durability

• Exceptional durability to 20 years
• Consistent performance in a multitude of published studies

Tissue treatment

• Treated with XenoLogiX process, which removes binding sites for calcium
• Superior anticalcification results in animal studies†,2,3 compared to any other commercially available valve treatment

Hemodynamic performance

• Largest EOA of any stented tissue valve†
• Unprecedented 17-year hemodynamic stability

† No clinical data are available which evaluate the long-term impact of the XenoLogiX treatment in patients.

In patients over the age of 60, the actual risk of explant due to SVD is less than 10% at 20 years.1

The PERIMOUNT bioprosthesis is the world's most widely implanted tissue valve — period.

1 No clinical data are available which evaluate the long-term impact of the XenoLogiX treatment in patients.
The PERIMOUNT bioprosthesis is the world's most widely implanted tissue valve — period.

- Exceptional durability to 20 years
- Consistent performance in a multitude of published studies
- Treated with XenoLogiX process, which removes binding sites for calcium
- Superior anticalcification results in animal studies†, compared to any other commercially available valve treatment
- Largest EOA of any stented tissue valve
- Unprecedented 17-year hemodynamic stability
- Hemodynamic performance
- Tissue treatment

Compromise?

Uncompromised

Uncompromised

Uncompromised

In patients over the age of 60, the actual risk of explant due to SVD is less than 10% at 20 years.1

† No clinical data are available which evaluate the long-term impact of the XenoLogiX treatment in patients.